Sirolimus is a mammalian target of rapamycin (mTOR) inhibitor indicated for therapeutic immunosuppression following solid organ transplantation. It has also been shown to decrease skin cancer risk in transplant recipients. We present a case of rapid progression and de novo formation of leg ulcers in a renal transplant recipient coincident with sirolimus therapy.
A woman in her 70s with a history of renal transplantation and multiple cutaneous squamous cell carcinomas (SCCs) presented with nonhealing wounds of the lower extremities. She had a history of diabetes, venous insufficiency, and peripheral arterial disease. Medications included tacrolimus, 2 mg/d, and prednisone, 5 mg/d, for immunosuppression, and acitretin, 20 mg/d, for skin cancer prophylaxis.
Totonchy MB, Colegio OR, Christensen SR. Sirolimus-Associated Rapid Progression of Leg Ulcers in a Renal Transplant Recipient. JAMA Dermatol. 2017;153(1):105–106. doi:10.1001/jamadermatol.2016.3546
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: